HER2-targeted oncolytic virus plus custom immune cells for solid cancers
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced HER2-positive solid cancer confirmed from tumor testing (IHC).
- Your cancer cannot be cured with standard options like surgery, radiation, or chemotherapy (and standard treatments have been tried or are not available).
- Your cancer has gotten worse after first-line treatment, or you have no effective remaining treatment options.
- You have at least one tumor spot that doctors can safely inject directly, and you have scan results showing measurable disease.
- You can likely tolerate treatment: you’re an adult (18+), expected to live more than 12 weeks, and blood organ tests meet required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests a new treatment that combines a virus-based gene therapy injected directly into tumors with an immunotherapy drug. It aims to help people with advanced head and neck or esophageal cancer who have already tried other treatments.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.